|
gptkbp:instanceOf
|
alkaloid
Hallucinogen
|
|
gptkbp:CASNumber
|
520-52-5
|
|
gptkbp:category
|
psychedelic
alkaloid
Hallucinogen
|
|
gptkbp:chemicalFormula
|
gptkb:C12H17N2O4P
|
|
gptkbp:color
|
white (pure form)
|
|
gptkbp:discoveredBy
|
gptkb:Albert_Hofmann
|
|
gptkbp:discoveredIn
|
1958
|
|
gptkbp:effect
|
euphoria
hallucinations
altered perception
spiritual experiences
|
|
gptkbp:firstIsolatedFrom
|
gptkb:Psilocybe_mexicana
|
|
gptkbp:foundIn
|
gptkb:Psilocybe_cubensis
gptkb:Psilocybe_cyanescens
gptkb:Psilocybe_semilanceata
|
|
gptkbp:halfLife
|
2.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Psilocybin
|
|
gptkbp:IUPACName
|
gptkb:3-[2-(dimethylamino)ethyl]-1H-indol-4-yl_dihydrogen_phosphate
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
Controlled substance (various countries)
|
|
gptkbp:mainStreet
|
magic mushroom compound
shrooms
|
|
gptkbp:mechanismOfAction
|
5-HT2A receptor agonist
|
|
gptkbp:medicalResearch
|
addiction treatment
PTSD treatment
depression treatment
anxiety treatment
|
|
gptkbp:meltingPoint
|
220 °C (decomposes)
|
|
gptkbp:metabolism
|
gptkb:psilocin
|
|
gptkbp:molecularWeight
|
284.25 g/mol
|
|
gptkbp:notAddictive
|
true
|
|
gptkbp:PubChem_CID
|
CHEMBL651
10624
CHEBI:8614
|
|
gptkbp:riskFactor
|
gptkb:hallucinogen_persisting_perception_disorder
psychological distress
anxiety
paranoia
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
intranasal
|
|
gptkbp:solubility
|
water-soluble
|
|
gptkbp:toleranceDevelops
|
true
|
|
gptkbp:UNII
|
1PSQ49J53A
|
|
gptkbp:usedFor
|
clinical research
recreational purposes
spiritual rituals
|
|
gptkbp:bfsParent
|
gptkb:Psilocybe_azurescens
gptkb:Schedule_I
gptkb:Hallucinogen
gptkb:Schedule_I_(US)
|
|
gptkbp:bfsLayer
|
6
|